X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs LUPIN LTD - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER LUPIN LTD PFIZER/
LUPIN LTD
 
P/E (TTM) x 33.4 161.7 20.7% View Chart
P/BV x 5.0 3.0 165.4% View Chart
Dividend Yield % 0.8 0.8 91.2%  

Financials

 PFIZER   LUPIN LTD
EQUITY SHARE DATA
    PFIZER
Mar-17
LUPIN LTD
Mar-17
PFIZER/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,0551,750 117.4%   
Low Rs1,6511,384 119.3%   
Sales per share (Unadj.) Rs429.8387.4 110.9%  
Earnings per share (Unadj.) Rs73.656.6 130.0%  
Cash flow per share (Unadj.) Rs87.476.8 113.7%  
Dividends per share (Unadj.) Rs20.007.50 266.7%  
Dividend yield (eoy) %1.10.5 225.5%  
Book value per share (Unadj.) Rs528.7298.9 176.9%  
Shares outstanding (eoy) m45.75451.58 10.1%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.34.0 106.6%   
Avg P/E ratio x25.227.7 91.0%  
P/CF ratio (eoy) x21.220.4 104.0%  
Price / Book Value ratio x3.55.2 66.9%  
Dividend payout %27.213.2 205.2%   
Avg Mkt Cap Rs m84,777707,513 12.0%   
No. of employees `0002.816.8 16.9%   
Total wages/salary Rs m3,03928,495 10.7%   
Avg. sales/employee Rs Th6,925.910,418.3 66.5%   
Avg. wages/employee Rs Th1,070.41,697.0 63.1%   
Avg. net profit/employee Rs Th1,186.31,523.0 77.9%   
INCOME DATA
Net Sales Rs m19,663174,943 11.2%  
Other income Rs m1,0121,065 95.0%   
Total revenues Rs m20,674176,008 11.7%   
Gross profit Rs m3,49144,931 7.8%  
Depreciation Rs m6299,122 6.9%   
Interest Rs m101,525 0.6%   
Profit before tax Rs m3,86435,349 10.9%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,8019,785 18.4%   
Profit after tax Rs m3,36825,575 13.2%  
Gross profit margin %17.825.7 69.1%  
Effective tax rate %46.627.7 168.3%   
Net profit margin %17.114.6 117.2%  
BALANCE SHEET DATA
Current assets Rs m20,789119,542 17.4%   
Current liabilities Rs m7,87061,206 12.9%   
Net working cap to sales %65.733.3 197.0%  
Current ratio x2.62.0 135.3%  
Inventory Days Days6076 78.6%  
Debtors Days Days2290 24.9%  
Net fixed assets Rs m9,175131,660 7.0%   
Share capital Rs m458903 50.7%   
"Free" reserves Rs m23,731134,073 17.7%   
Net worth Rs m24,189134,976 17.9%   
Long term debt Rs m2556,478 0.0%   
Total assets Rs m32,706266,073 12.3%  
Interest coverage x403.524.2 1,669.1%   
Debt to equity ratio x00.4 0.2%  
Sales to assets ratio x0.60.7 91.4%   
Return on assets %10.310.2 101.4%  
Return on equity %13.918.9 73.5%  
Return on capital %21.419.3 111.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6381,885 0.1%   
Fx outflow Rs m4,06721,506 18.9%   
Net fx Rs m-4,00460,378 -6.6%   
CASH FLOW
From Operations Rs m3,28841,148 8.0%  
From Investments Rs m-2,496-25,287 9.9%  
From Financial Activity Rs m-8264,332 -19.1%  
Net Cashflow Rs m-3520,193 -0.2%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 63.9 0.2 31,950.0%  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 4.9 31.9 15.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.1 234.7%  
Shareholders   85,207 98,259 86.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 20, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS